Minerva endocrinology最新文献

{"title":"Obesity-cancer convergence in the destiny of an adipocyte.","authors":"Natalia Malara, Antonio Aversa, Francesco Riva","doi":"10.23736/S2724-6507.26.04575-6","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04575-6","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital platforms influence users and their eating habits.","authors":"Giulia Guarino, Renata Bracale, Martina Ingrosso, Giovanna Muscogiuri, Concetta Vaccaro","doi":"10.23736/S2724-6507.26.04535-5","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04535-5","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147776222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of hypoglycemic agents on glycemic control and cognitive decline in older adults with type 2 diabetes: real-world evidence on glucagon like peptide 1 receptor agonists.","authors":"Benedetta DI Marzio, Giulia Gasparini, Andrea Ambrosio, Alessandra Coin, Luca Filipponi, Giovanni Sartore, Elisabetta Ferra, Mario V Papa, Adele Ravelli, Chiara Ceolin, Marina DE Rui, Bruno M Zanforlini, Chiara Curreri, Anna Bertocco, Maria Devita, Giuseppe Sergi","doi":"10.23736/S2724-6507.26.04501-X","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04501-X","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is frequently associated with cognitive decline in the older population. Although optimal glycemic control is known to be essential for disease management, the impact of hypoglycemic agents on cognitive function remains poorly investigated.</p><p><strong>Methods: </strong>This retrospective study included 93 geriatric outpatients with T2DM. Hypoglycemic treatments consisted of metformin, sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors, and insulin. Patient evaluations included glycated hemoglobin (HbA1c) measurements, Standardized Mini-Mental State Examination (MMSE), and Mini Nutritional Assessment (MNA).</p><p><strong>Results: </strong>After one year of treatment, patients exhibited a significant reduction in HbA1c levels (from 8.06% [±1.19] to 7.19% [±0.84], P<0.001), improvement of MMSE scores (from 25.87 [±3.09] to 27.47 [±2.9], P<0.001). Regression analysis identified GLP-1RAs as the most effective agent in improving glycemic control (P<0.001) and cognitive function (P=0.016). Treatment with GLP-1RAs was associated with a reduction in MNA scores (P<0.001), though these remained above the malnutrition threshold.</p><p><strong>Conclusions: </strong>Our findings suggest that improved glycemic control may help slow cognitive decline in older patients with T2DM. Among the drug classes examined, GLP-1RAs showed the largest reductions in HbA1c and were linked to greater MMSE score gains.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-time continuous glucose monitoring with subcutaneously inserted sensor correlates better than subcutaneously implantable sensor with glycated hemoglobin, glycated albumin and fructosamine.","authors":"Sanja Medenica, Roberto Negro, Djordje Popovic, Michele Chicone, Luigi E Greco","doi":"10.23736/S2724-6507.26.04486-6","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04486-6","url":null,"abstract":"<p><strong>Background: </strong>Real-time continuous glucose monitoring (RT-CGM) is widely used in patients with type 1 diabetes (T1D) to improve glycemic control by reducing postprandial glucose peaks and hypoglycemic episodes. In addition, traditional biomarkers such as glycated hemoglobin (HbA1c), glycated albumin, and fructosamine provide retrospective estimates of glucose regulation over varying timeframes. This study aimed to evaluate the correlation between these biomarkers and glycemic metrics obtained from two types of RT-CGM systems: an implantable sensor (Eversense E3) and subcutaneously inserted sensors (Dexcom G6 and Guardian 4).</p><p><strong>Methods: </strong>We analyzed data from 35 patients with T1D: 13 used the Eversense E3 system, and 22 used Dexcom G6 or Guardian 4. Mean blood glucose (MBG) and time in range (TIR) were assessed at multiple time points and correlated with HbA1c, glycated albumin, and fructosamine levels.</p><p><strong>Results: </strong>In the Eversense group, no significant correlation was observed between CGM-derived metrics and any of the biomarkers. Conversely, in the Dexcom/Guardian group, MBG and TIR demonstrated significant correlations with all biomarkers, showing large effect sizes for HbA1c and fructosamine, and medium for glycated albumin.</p><p><strong>Conclusions: </strong>These findings suggest that the Dexcom G6 and Guardian 4 systems more reliably reflect established biochemical markers of mid- to long-term glucose control, while Eversense may be less consistent in this regard. This highlights the importance of sensor selection when interpreting CGM data for clinical or research applications in diabetes management.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147513367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of survodutide: a new dual acting agonist.","authors":"Meenakshi R Yathindra, Ayush Bhattacharjee, Nikhil Pundir, Pooja Patel, Nidhi E Jacob, Preeti E Jossy, Rajmohan Seetharaman","doi":"10.23736/S2724-6507.26.04406-4","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04406-4","url":null,"abstract":"<p><p>Survodutide represents an innovative approach to obesity management and metabolic-associated fatty liver disease (MAFLD). These conditions, often closely linked with type 2 diabetes (T2DM) and cardiovascular diseases, demand effective treatment strategies. Survodutide acts by targeting both GLP-1 and glucagon receptors. This new dual agonist offers potential transformative benefits, with early clinical trials showcasing significant weight loss and improvements in metabolic markers. Survodutide's mechanism of action includes appetite regulation, enhanced glucose metabolism, and increased energy expenditure, making it a promising option for those struggling with obesity and related health issues. This review assesses Survodutide's pharmacology, efficacy, and safety in MASH and obesity, while also outlining its broader metabolic and cardiovascular benefits. It compares Survodutide's dual-agonist mechanism and clinical performance with single-target incretin therapies to clarify its potential role in the evolving treatment landscape. While the initial results are promising, the review emphasizes the importance of continued research to fully understand Survodutide's long-term safety and effectiveness. Ongoing trials will provide critical insights into its overall impact, side effects, patient response, and cost considerations. This article highlights Survodutide's potential in the treatment of obesity and metabolic disordersand evaluates its place in therapy for seeking improved outcomes.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amylin role in glucose homeostasis and β-cell function: a robust justification.","authors":"Suad H Almasoudi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Duaa Eliwa, Gaber E Batiha","doi":"10.23736/S2724-6507.26.04508-2","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04508-2","url":null,"abstract":"<p><p>Amylin is a peptide hormone co-secreted with insulin from pancreatic β-cells that plays a crucial role in glucose homeostasis. Amylin by inhibiting glucagon secretion, slowing gastric emptying, and reducing food intake improves blood glucose and insulin sensitivity. However, emerging evidence suggests that amylin may also contribute to β-cell dysfunction and the development of insulin resistance (IR) in type 2 diabetes (T2D). This review explores the dual roles of amylin in T2D pathogenesis and management, highlighting its therapeutic and pathogenic implications. High amylin levels are associated with amyloid fibril formation, β-cell cytotoxicity, and progression of T2D complications. Conversely, amylin analogues have been shown to improve glycemic control, promote weight loss, and enhance energy balance via dual activation of amylin and calcitonin receptors in the hypothalamus. Experimental and clinical data demonstrate that both detrimental and protective effects of amylin are depending on concentration, duration, and receptor interaction. Amylin and its analogues exhibit paradoxical actions in T2D, acting as both pathogenic and protective effects. While preclinical and limited clinical studies support their role in improving metabolic control, concerns about amyloidogenic toxicity persist. Therefore, further robust clinical trials are needed to clarify amylin's long-term safety and optimize its therapeutic potential in T2D management.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147444294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.","authors":"Giuseppe Seminara, Marco Leuzzi, Leonardo Meduri, Emanuela A Greco, Antonio Aversa","doi":"10.23736/S2724-6507.26.04541-0","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04541-0","url":null,"abstract":"<p><strong>Background: </strong>Male obesity-associated hypogonadism promotes a vicious cycle of sarcopenic obesity and increased cardiometabolic risk. Although tirzepatide is highly effective for weight loss, a subset of \"late responders\" has been reported, and treatment-induced lean body mass (LBM) depletion remains a significant clinical concern. This pilot study evaluated the efficacy of adding testosterone undecanoate (TRT) to tirzepatide in this specific population.</p><p><strong>Methods: </strong>We enrolled 10 obese men (age range: 35-44 years; Body Mass Index [BMI] = 35.8±2.1 kg/m²) with functional secondary hypogonadism after ≥3 months of treatment with tirzepatide and <5% total body weight loss (late responders). Patients were then allocated to group A (tirzepatide monotherapy, N.=5) or group B (combined tirzepatide plus testosterone undecanoate 1000 mg/im, N.=5) and re-evaluated after 6 months. DXA-derived body composition, hormonal and metabolic profiles, sexual function (International Index of Erectile Function-5, IIEF-5), and physical activity levels (Global Physical Activity Questionnaire) were evaluated.</p><p><strong>Results: </strong>At 6 months, group B demonstrated significantly greater body weight and fat mass reduction compared to group A (P<0.05). Notably, while group A experienced progressive LBM loss, group B achieved significant LBM recovery (66.1±3.1 kg vs. 63.4±3.0 kg in group A, P<0.01). group B showed restored testosterone levels, leading to superior improvements in insulin sensitivity (HOMA-IR: 2.9±0.6 vs. 3.8±0.7, P<0.01) and sexual health (IIEF-5: 23.2±2.1 vs. 18.0±1.5, P<0.001). Additionally, group B exhibited nearly doubled physical activity levels (P<0.001), suggesting a synergy between hormonal restoration and increased exercise motivation.</p><p><strong>Conclusions: </strong>Our preliminary findings suggest that adding TRT to tirzepatide in late tirzepatide responders who are hypogonadal may optimize weight loss quality, prevent muscle depletion, and restore sexual and metabolic health. This dual pharmacological approach represents a promising precision medicine strategy for managing complex phenotypes of male obesity-associated hypogonadism.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion by the Italian Society of Gynecology of the Third Age (SIGiTE) and the Italian Society of Menopause (SIM) on diagnosis and treatment of premature ovarian insufficiency.","authors":"Anna Capozzi, Simona Ambroggio, Angelo Cagnacci, Marco Gambacciani, Stefano Lello, Costantino DI Carlo","doi":"10.23736/S2724-6507.25.04422-7","DOIUrl":"10.23736/S2724-6507.25.04422-7","url":null,"abstract":"<p><p>Premature ovarian insufficiency (POI) is a critical condition affecting young women before the median age of menopause and consisting of spontaneous oligo-amenorrhea for at least four months associated with follicle stimulating hormone (FSH) levels ≥25 UI/L detected before 40 years of age. Several causes like genetic abnormalities, autoimmune diseases, drugs and/or pelvic surgery may favor this condition that is associated with a deeper clinical impact on women's health compared to physiological menopause. Specifically, cardiovascular and musculoskeletal systems as well as brain could be especially affected by the early loss of ovarian hormones. Therefore, appropriate treatment is necessary to adequately narrow the biological gap with the average age of menopause. Hormone replacement therapy (HRT) is the treatment of choice, regardless of the presence of neurovegetative symptoms. Transdermal high dosage of natural estradiol is generally preferred to guarantee the preservation of cardio-metabolic and bone health. When contraception is required, oral estroprogestins (EPs) maybe considered. A referral to reproductive experts for fertility preservation techniques should be considered case by case.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"88-95"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnitude and time course of urinary iodine excretion in patients after amiodarone therapy.","authors":"Giulia Marchionni, Giuseppe Pinto, Massimo Locatelli, Roberto Spoladore, Luca Foppoli, Giuseppe Monaca, Alberto Margonato, Gabriele Fragasso","doi":"10.23736/S2724-6507.24.04213-1","DOIUrl":"10.23736/S2724-6507.24.04213-1","url":null,"abstract":"<p><strong>Background: </strong>Amiodarone is a source of iodine excess that may persist in the body for long time after its withdrawal. The aim of the present analysis was to evaluate the magnitude and long-term time course of 24-h urinary iodine (UI) excretion in patients on antiarrhythmic therapy with amiodarone.</p><p><strong>Methods: </strong>24-h UI excretion and thyroid function were evaluated in 67 patients on amiodarone therapy. All patients were clinically and biochemically euthyroid before starting treatment and were followed-up by 6-month measurements of 24-h UI excretion and plasma thyroid hormones levels.</p><p><strong>Results: </strong>Upon amiodarone withdrawal, normal range of UI was achieved after a mean time of 15.2±7.7 months. Since amiodarone initiation, 20 patients developed thyroid dysfunction. No differences were observed in terms of treatment length or median UI levels between patients remaining euthyroid and those developing thyroid dysfunction: median UI in the euthyroid group was 8094 µg/24 h (Interquartile Range [IQR]: 4082-10766) vs. 10851 µg/24 h (IQR: 8529-12804) in the thyroid dysfunction group at 6 months (P=0.176) and 8651 µg/24 h (IQR: 6924-11574) vs. 8551 µg/24 h (IQR: 4916-13580) at one year from amiodarone initiation (P=0.886). The occurrence of thyroid dysfunction was equally distributed among patients taking amiodarone for more than one year versus those under treatment for less than one year.</p><p><strong>Conclusions: </strong>These results confirm the long-lasting total-body iodine stores and consequent excretion in patients after amiodarone withdrawal. These long-lasting iodine stores might be taken into special account in patients necessitating therapy with radioactive iodine and for long-term monitoring of thyroid function after amiodarone discontinuation.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"17-22"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic health and quality of life in patients with Polycystic Ovary Syndrome: a cross-sectional study.","authors":"Konstantin Hofmann, Susanne Singer, Susanne Theis, Annette Hasenburg, Roxana Schwab, Christine Skala","doi":"10.23736/S2724-6507.25.04245-9","DOIUrl":"10.23736/S2724-6507.25.04245-9","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is an endocrine disorder that can result in reduced health-related quality of life (HRQOL). Metabolic changes, particularly insulin resistance and obesity, play a significant role in PCOS pathogenesis. This study examined associations between metabolic factors and HRQOL in PCOS patients.</p><p><strong>Methods: </strong>A cross-sectional study of 77 patients was conducted at University Medical Center Mainz. At the time of inclusion in the study, patients had to be over 18 and not undergoing active PCOS therapy. A desire to conceive or fertility therapy led to exclusion. Participants were over 18, not undergoing PCOS therapy, and not seeking pregnancy. HRQOL and psychological distress were measured using the Modified-PCOS-Questionnaire (MPCOSQ) and Hospital Anxiety and Depression Scale (HADS). Linear regression analyses assessed associations between metabolic markers and HRQOL, with significant variables included in a multivariate model.</p><p><strong>Results: </strong>Worsening metabolic markers were linked to lower HRQOL, especially in body hair and menstrual symptom domains. Markers such as HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) levels (P=0.040), elevated VAI (Visceral Adiposity Index) (P=0.035), and increased FLI (Fatty Liver Index) (P=0.023) were associated with diminished HRQOL. In the multivariate regression analysis, only a BMI ≥25kg/m² (P=0.001) emerged as a statistically significant value.</p><p><strong>Conclusions: </strong>This study showed a significant correlation between metabolic markers, including BMI, FLI, VAI, HOMA-IR, and HRQOL in PCOS patients. BMI was the most meaningful predictor for HRQOL. BMI, despite being controversial and prone to errors, may be more indicative of HRQOL than specific metabolic markers.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"34-42"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}